Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-04-22 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2025-04-22 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled "Déclaration des transactions sur actions propre" which translates to "Declaration of transactions on own shares." It details daily aggregated and transaction-by-transaction data of Sanofi's own share buybacks over a specific period (April 14 to April 17, 2025). The content includes volumes, prices, transaction times, and market codes, consistent with a report on the company's repurchase of its own shares. There is no indication that this is an announcement of a report or a certification. The document is substantive and detailed, not a brief notice. Therefore, it fits the category of "Transaction in Own Shares" (POS).
2025-04-18 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states in the title and content that it is a "Disclosure of trading in own shares" and details the purchases of Sanofi's own shares over a specific period (14 April 2025 to 17 April 2025). This directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which maps to the filing type code POS (Transaction in Own Shares).
2025-04-18 English
Communiqué de presse : Le Dupixent devient le premier nouveau médicament ciblé approuvé aux États-Unis depuis plus de dix ans pour le traitement de l’urticaire chronique spontanée
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces the FDA approval of Dupixent for Chronic Spontaneous Urticaria (CSU). It details the clinical trial results (Phase III studies A, B, and C), quotes executives from Sanofi and Regeneron, and provides background information on the drug and the disease. This format—a formal announcement of a significant corporate/product event, often released to the public and media—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of a major regulatory event (FDA approval) and includes quotes and scientific data, it functions as an initial release of important news, fitting the description of an Earnings Release (ER) better than a general RNS, although it is not strictly financial earnings. However, given the options, ER is the closest fit for a major product/regulatory milestone announcement press release. It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a Report Publication Announcement (RPA) as it contains the substance of the news, not just an announcement that a report is available.
2025-04-18 French
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Regulatory Filings Classification · 100% confidence The document is explicitly titled '# **Press Release**' and announces the FDA approval of Dupixent for chronic spontaneous urticaria (CSU). It contains quotes from company executives (Sanofi and Regeneron), details about clinical trial data, and standard boilerplate sections like 'About CSU', 'About Dupixent', and 'Sanofi forward-looking statements'. This format is characteristic of an initial public announcement of significant corporate news, such as a regulatory milestone or financial result. Given the options, this is not a comprehensive Annual Report (10-K), an Interim Report (IR), or a detailed Management Discussion & Analysis (MDA). It is the initial release of key results/news. The closest fit among the provided codes is 'ER' (Earnings Release), which often serves as the general category for initial press releases announcing major corporate events, even if not strictly quarterly earnings. However, since this is a regulatory approval announcement, and not explicitly an earnings announcement, we must check other categories. It is not a Call Transcript (CT), Investor Presentation (IP), or Proxy Statement (PSI). It is a formal announcement of a major event. While 'ER' is often used for earnings, in the context of regulatory approvals, sometimes 'RNS' (Regulatory Filings) is used as a catch-all. However, 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document is an initial announcement of a regulatory event, not financial results. Since there is no specific code for 'Regulatory Approval Announcement', and it is a formal, structured press release, it fits best under the general regulatory/announcement category. Given the options, 'RNS' (Regulatory Filings - General regulatory announcements and fallback category for miscellaneous filings) is the most appropriate classification for a major, non-earnings-related regulatory milestone announcement that doesn't fit the other specific categories like DIV, CAP, or DLST.
2025-04-18 English
6-K
Regulatory Filings
2025-04-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.